Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor
- PMID: 17317585
- DOI: 10.1016/j.bbmt.2006.10.027
Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor
Abstract
The responsible human leukocyte antigen (HLA) locus and the role of killer immunoglobulin-like receptor (KIR) ligand matching on transplantation outcome were simultaneously identified by multivariate analysis in 1790 patients with leukemia who underwent transplantation with T-cell-replete marrow from an unrelated donor (UR-BMT) through the Japan Marrow Donor Program. The graft-versus-leukemia (GVL) effect depended on leukemia cell type. HLA-C mismatch reduced the relapse rate in acute lymphoblastic leukemia (ALL) (hazard ratio [HR] = 0.47; P = .003), and HLA-DPB1 mismatch reduced it in chronic myeloid leukemia (CML) (HR = 0.35; P < .001). In contrast, KIR2DL ligand mismatch in the graft-versus-host (GVH) direction (KIR-L-MM-G) increased in ALL (HR = 2.55; P = .017). An increased rejection rate was observed in KIR2DL ligand mismatch in the host-versus-graft direction (HR = 4.39; P = .012). Acute GVH disease (GVHD) was increased not only in the mismatch of HLA-A, -B, -C, and -DPB1, but also in KIR-L-MM-G. As a whole, the mismatch of HLA-A, -B, and -DQB1 locus and KIR-L-MM-G resulted in increased mortality. In conclusion, not only the mismatch of HLA-C and -DPB1, but also KIR-L-MM-G affected leukemia relapse, which should be considered based on leukemia cell type. Furthermore, KIR-L-MM induced adverse effects on acute GVHD (aGVHD) and rejection, and brought no survival benefits to patients with T-cell-replete UR-BMT.
Similar articles
-
Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligand-mismatched T cell-replete unrelated bone marrow transplantation.Biol Blood Marrow Transplant. 2008 Jan;14(1):75-87. doi: 10.1016/j.bbmt.2007.09.012. Biol Blood Marrow Transplant. 2008. PMID: 18158964
-
The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry.Biol Blood Marrow Transplant. 2006 Aug;12(8):876-84. doi: 10.1016/j.bbmt.2006.05.007. Biol Blood Marrow Transplant. 2006. PMID: 16864058
-
Prognosis after unmanipulated HLA-haploidentical blood and marrow transplantation is correlated to the numbers of KIR ligands in recipients.Eur J Haematol. 2007 Apr;78(4):338-46. doi: 10.1111/j.1600-0609.2007.00822.x. Eur J Haematol. 2007. PMID: 17378893
-
Is there an impact of killer cell immunoglobulin-like receptors and KIR-ligand incompatibilities on outcomes after unrelated cord blood stem cell transplantation?Best Pract Res Clin Haematol. 2010 Jun;23(2):283-90. doi: 10.1016/j.beha.2010.05.005. Best Pract Res Clin Haematol. 2010. PMID: 20837340 Review.
-
Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.Dan Med Bull. 2002 May;49(2):89-108. Dan Med Bull. 2002. PMID: 12064093 Review.
Cited by
-
A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation.PLoS One. 2011;6(10):e26229. doi: 10.1371/journal.pone.0026229. Epub 2011 Oct 20. PLoS One. 2011. PMID: 22028838 Free PMC article.
-
Molecular disparity in human leukocyte antigens is associated with outcomes in haploidentical stem cell transplantation.Blood Adv. 2020 Aug 11;4(15):3474-3485. doi: 10.1182/bloodadvances.2019000797. Blood Adv. 2020. PMID: 32726398 Free PMC article.
-
Immunotherapeutic approaches to treat multiple myeloma.Hum Vaccin Immunother. 2014;10(4):896-910. doi: 10.4161/hv.27380. Epub 2013 Dec 11. Hum Vaccin Immunother. 2014. PMID: 24335570 Free PMC article. Review.
-
Donor Heme Oxygenase-1 Promoter Gene Polymorphism Predicts Survival after Unrelated Bone Marrow Transplantation for High-Risk Patients.Cancers (Basel). 2020 Feb 12;12(2):424. doi: 10.3390/cancers12020424. Cancers (Basel). 2020. PMID: 32059452 Free PMC article.
-
New advances in hematopoietic cell transplantation.Curr Opin Hematol. 2008 Nov;15(6):549-54. doi: 10.1097/MOH.0b013e328311891f. Curr Opin Hematol. 2008. PMID: 18832924 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials